Preemies' Blood Type Tied to Risk for Necrotizing Enterocolitis
|
By LabMedica International staff writers Posted on 21 Jul 2021 |

Image: Axiom Genome-Wide Population-Optimized Human Arrays are genotyping panels that offer the best genetic coverage of rare and common variants for genome-wide disease association studies (Photo courtesy of Thermo Fisher Scientific)
Necrotizing enterocolitis (NEC) and focal intestinal perforation (FIP) are two of the most common emergencies of the gastrointestinal tract in preterm infants with very low birth weight (VLBW). The etiology and pathogenesis of NEC and FIP remain poorly understood.
Although FIP and NEC have been recognized as distinct entities, the clinical features and timing of presentation are frequently overlapping, making both diseases clinically indistinguishable in many cases. NEC typically occurs in infants born between 22 and 28 weeks of gestation within the second or third week of life. The gestational age of children developing FIP ranges between 22 and 27 weeks with intestinal perforation occurring within the first or second week of life.
Pediatricians at the University of Leipzig (Leipzig, Germany) and their colleagues enrolled in a prospective cohort study infants with a birth weight below 1,500 grams and gestational age below 37 weeks from 43 participating tertiary German neonatal intensive care units. The study included 10,257 infants with very low birth weight, 441 of whom required surgery for NEC/FIP. Data were collected from every infant on important maternal, fetal, and neonatal parameters, including maternal ethnic origin, sex, singleton versus multiple births, fetal malformation, pharmacological or surgical treated patent ductus arteriosus (PDA), sepsis, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL).
Patients’ data and samples were coded before genotyping and analysis. DNA was extracted using standard protocols for commercial DNA purification kits (Gentra Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip genotyping was done by using ‘Axiom CEU’ (Affymetrix, Santa Clara, CA, USA) or by using ‘Global Screening Array (GSA)’ (Illumina, San Diego, CA, USA). The ABO gene was determined according to two SNPs (rs8176746 and rs8176719).
The team reported that most infants had type A blood (46.5%), followed by type O (34.5%), type B (13%), and type AB (6%). In regards to birth weight, mode of delivery, gestational age, gender, and corticosteroid exposure, no differences were reported according to blood type. Most infants had an average gestational age of 28.5 weeks, and the average birth weight was 1,051 grams for the AB blood group and 1,037 grams for the non-AB group. NEC/FIP requiring surgery was observed in 6.2% of infants with AB blood versus 4.2% of those with non-AB blood and 4.4% of those with type O blood. Mortality from NEC/FIP was 7.7% for the AB blood type group and 6.8% for the non-AB blood groups.
The authors concluded that they had demonstrated that among VLBW infants, blood group AB is associated with an increased risk of NEC/FIP. Therefore, blood group AB may be considered as an additional risk factor for NEC/FIP. The underlying mechanism of the blood group AB in NEC/FIP development, including potential interactions between intestinal bacteria and histo-blood group antigens (HBGAs) needs to be further elucidated. The study was published on July 2, 2021 in the journal Nature Scientific Reports.
Related Links:
University of Leipzig
Qiagen
Affymetrix
Illumina
Although FIP and NEC have been recognized as distinct entities, the clinical features and timing of presentation are frequently overlapping, making both diseases clinically indistinguishable in many cases. NEC typically occurs in infants born between 22 and 28 weeks of gestation within the second or third week of life. The gestational age of children developing FIP ranges between 22 and 27 weeks with intestinal perforation occurring within the first or second week of life.
Pediatricians at the University of Leipzig (Leipzig, Germany) and their colleagues enrolled in a prospective cohort study infants with a birth weight below 1,500 grams and gestational age below 37 weeks from 43 participating tertiary German neonatal intensive care units. The study included 10,257 infants with very low birth weight, 441 of whom required surgery for NEC/FIP. Data were collected from every infant on important maternal, fetal, and neonatal parameters, including maternal ethnic origin, sex, singleton versus multiple births, fetal malformation, pharmacological or surgical treated patent ductus arteriosus (PDA), sepsis, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL).
Patients’ data and samples were coded before genotyping and analysis. DNA was extracted using standard protocols for commercial DNA purification kits (Gentra Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip genotyping was done by using ‘Axiom CEU’ (Affymetrix, Santa Clara, CA, USA) or by using ‘Global Screening Array (GSA)’ (Illumina, San Diego, CA, USA). The ABO gene was determined according to two SNPs (rs8176746 and rs8176719).
The team reported that most infants had type A blood (46.5%), followed by type O (34.5%), type B (13%), and type AB (6%). In regards to birth weight, mode of delivery, gestational age, gender, and corticosteroid exposure, no differences were reported according to blood type. Most infants had an average gestational age of 28.5 weeks, and the average birth weight was 1,051 grams for the AB blood group and 1,037 grams for the non-AB group. NEC/FIP requiring surgery was observed in 6.2% of infants with AB blood versus 4.2% of those with non-AB blood and 4.4% of those with type O blood. Mortality from NEC/FIP was 7.7% for the AB blood type group and 6.8% for the non-AB blood groups.
The authors concluded that they had demonstrated that among VLBW infants, blood group AB is associated with an increased risk of NEC/FIP. Therefore, blood group AB may be considered as an additional risk factor for NEC/FIP. The underlying mechanism of the blood group AB in NEC/FIP development, including potential interactions between intestinal bacteria and histo-blood group antigens (HBGAs) needs to be further elucidated. The study was published on July 2, 2021 in the journal Nature Scientific Reports.
Related Links:
University of Leipzig
Qiagen
Affymetrix
Illumina
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







